Top 10: AI Consulting Firms for Pharma and Life Sciences

AI adoption in pharma is shifting from isolated pilots to enterprise-scale deployment. Generative AI alone could unlock significant economic value across the life sciences sector, according to McKinsey (2024). In parallel, regulators such as the U.S. Food and Drug Administration (FDA) continue to expand guidance on AI-assisted drug development, reinforcing the need for structured, compliant implementation.

As a result, AI consulting firms are moving beyond experimentation support. Their role increasingly centres on embedding AI and analytics solutions into core workflows – helping organisations translate data into operational outcomes across clinical, commercial and operational functions.

ZS

Founded: 1983 
Headquarters: Evanston, Illinois, US 
Employees: ~15,000 
Global offices: 35+

Within pharma and life sciences, ZS operates as a specialist in AI and analytics consulting because it builds knowledge of more than 40 years of industry data, compliance and healthcare workflows directly into its AI solutions. Its work delivers end-to-end impact across discovery, clinical development, commercial strategy and patient engagement. ZS helps organisations achieve measurable enterprise outcomes by redesigning recurring decisions as AI-native systems within value streams – connecting insights directly to execution to drive sustained performance.

ZS helps life sciences organisations connect commercial, clinical and operational signals within a unified, governed decision intelligence framework, improving visibility and coordination across a range of life sciences functions. A core element of its approach is the use of outcomes-focused transformation roadmaps, supported by accelerators, sensing models and domain-specific data products. These capabilities empower organisations to move from retrospective reporting toward forward-looking, continuous decision cycles where teams sense-learn-decide and act quickly. 

QuantumBlack, AI by McKinsey

Founded: 2009 (acquired by McKinsey, 2015) 
Headquarters: London, UK / New York, US 
Employees: ~5,000+ AI specialists 
Global offices: 130+ (McKinsey network)

Through QuantumBlack, McKinsey combines AI strategy with advanced data science and engineering capabilities. Its work in pharma spans R&D, manufacturing and commercial operations, where AI models are integrated into broader transformation programmes.

Rather than focusing solely on tools, the firm emphasises capability building and organisational alignment. This approach enables AI initiatives to scale beyond isolated use cases and become embedded within enterprise processes. Its global network supports complex, multi-market engagements.

While McKinsey brings considerable scale and cross-industry experience, its pharma-specific assets are less specialised than those of domain-focused firms. It is often suited to organisations pursuing enterprise-wide transformation supported by strong strategic oversight.

Accenture Life Sciences

Founded: 1989 
Headquarters: Dublin, Ireland 
Employees: ~799,000 globally 
Global offices: 200+

Accenture delivers AI consulting solutions across the pharma value chain, combining strategy, implementation and managed services. Its work includes AI-enabled drug development support, data platform modernisation and commercial analytics transformation.

With a large global workforce and sustained investment in AI, Accenture supports complex programmes that require coordination across markets and systems. Its multi-cloud ecosystem enables integration with existing enterprise architectures.

The firm operates across industries, with life sciences representing one of several focus areas. Its strength lies in execution at scale, particularly for organisations seeking integrated technology and consulting support.

Deloitte Health AI

Founded: 1845 
Headquarters: London, UK 
Employees: ~470,000 globally 
Global offices: 150+

Deloitte focuses on AI governance, compliance and enterprise transformation within regulated industries. Its AI consulting solutions emphasise responsible AI frameworks, risk management and integration with existing systems.

In pharma, Deloitte supports use cases across clinical development, regulatory operations and broader performance improvement initiatives. Its approach ensures that AI deployment aligns with evolving regulatory expectations.

The firm’s ability to combine implementation with governance structures makes it often relevant for organisations operating in complex compliance environments.

Boston Consulting Group X

Founded: 2022 
Headquarters: Boston, Massachusetts, US 
Employees: ~3,000 engineers and designers 
Global offices: 100+ (BCG network)

BCG X integrates consulting with engineering and design capabilities to develop AI solutions that can be deployed at scale. In pharma, its work spans drug discovery, clinical trials and commercial analytics.

The firm operates through a co-creation model, working alongside clients to design and implement solutions within existing operating environments. This approach helps reduce the gap between concept and execution.

Although BCG’s coverage extends across multiple industries, it brings structured methodologies and technical depth to AI deployment programmes.

IQVIA 

Founded: 2016 
Headquarters: Durham, North Carolina, US 
Employees: ~93,000 globally 
Global offices: 100+

IQVIA combines proprietary healthcare datasets with analytics-driven consulting services. Its AI capabilities are closely tied to datasets covering prescriptions, patient journeys and clinical activity.

This data foundation supports detailed insights across commercial and clinical domains, particularly in areas such as real-world evidence and market access. AI applications are often layered onto these datasets to enhance predictive capabilities.

While IQVIA brings strong domain relevance, its positioning remains more data-centric than strategy-led, with strengths in analytics-intensive engagements.

IBM Consulting

Founded: 1911 
Headquarters: Armonk, New York, US 
Employees: ~280,000 globally 
Global offices: 175+ countries

IBM Consulting focuses on integrating AI into enterprise technology environments, drawing on platforms such as watsonx. In pharma, this includes data modernisation, system interoperability and regulatory-compliant AI deployment.

Its work often centres on large organisations with complex legacy systems, where integration and governance are key considerations. The firm aligns AI capabilities with broader enterprise architecture.

This positioning makes IBM particularly relevant for organisations seeking to scale AI within established IT ecosystems.

Cognizant

Founded: 1994 
Headquarters: Teaneck, New Jersey, US
Employees: ~350,000 globally 
Global offices: 40+

Cognizant provides AI implementation and automation services across pharma and medtech organisations. Its capabilities include data engineering, process automation and AI-enabled operational improvements.

With established delivery capacity and partnerships with major cloud providers, the firm supports deployment at scale. Its work focuses on embedding AI within existing processes rather than redefining strategy.

This execution-led model makes Cognizant a practical choice for organisations looking to operationalise AI solutions efficiently.

Capgemini

Founded: 1967 
Headquarters: Paris, France 
Employees: ~340,000 globally 
Global offices: 50+ countries

Capgemini takes an engineering-led approach to AI consulting, focusing on scalable and production-ready solutions. In pharma, its work spans manufacturing, supply chain and R&D operations.

The firm emphasises integration within existing enterprise systems, ensuring that AI capabilities can be deployed consistently across functions. Its experience in regulated environments supports compliance requirements.

Its strengths are most evident in implementation and system-level transformation.

EY Health

Founded: 1989 
Headquarters: London, UK 
Employees: ~400,000 globally 
Global offices: 150+

EY’s approach to AI consulting centres on governance, compliance and value realisation. Its solutions are designed to align AI deployment with regulatory expectations and measurable business outcomes.

In pharma, the firm supports regulatory processes, financial operations and targeted transformation initiatives. Its work focuses on ensuring that AI investments translate into structured, auditable results.

This emphasis on oversight and accountability makes EY relevant for organisations prioritising risk management alongside innovation.